Claudia Vasconcelos, Sr. Medical Director, Global Head, Breast and Gyn TA at Parexel, shared a post on LinkedIn:
“Sharing the positive topline results from DESTINY-Breast09!
Trastuzumab deruxtecan (T-DXd) in combination with pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in PFS compared to taxane, trastuzumab and pertuzumab (THP) as 1st-line treatment for patients with HER2-positive metastatic breast cancer.
A protential practice-changing study for HER2+ MBC!”